Addiction

Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Conducted meetings with U.S. and select European regulatory agencies Received Notice of Exercise and upfront cash of $0.45 million from…

2 years ago

Scotiabank donates $1.35M to the MUHC Foundation to create a Montreal without hepatitis C

The transformative gift supports Montréal sans HépC, an ambitious community-based program to prevent and cure hepatitis C cases in Montreal…

2 years ago

Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business

Adial to receive potential development and commercial milestone payments of up to $83 million on the first three compounds plus…

2 years ago

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam

Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome  Tel Aviv, Israel / Vancouver, Canada, May…

2 years ago

Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical…

2 years ago

National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use Disorders

ROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced…

2 years ago

PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin

PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by…

2 years ago

Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits

SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients…

2 years ago

Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression

The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada,…

2 years ago

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE)…

2 years ago